Tse-I Lin

Tse-I Lin, Ph.D., is currently Vice President, Early Compound Development and Site Head of Aligos Therapeutics at the site in Leuven, Belgium. In this position, Dr. Lin serves as a member of the Senior Leadership Team. Tse-I started his professional career as a Post-Doc at Bayer Pharmaceutical in Germany. He subsequently joined JNJ/Tibotec BVBA in 2003 and worked for over 12 years at Janssen Pharmaceutical in antiviral drug discovery and development, focusing on HBV and HCV, including the HCV protease inhibitor, Simeprevir, which was launched in the US in 2013. In 2010, Tse-I took a leadership position in Shanghai, China for JNJ where he built the Antiviral R&D group. In 2013 he joined Roche as the Head of the Molecular Virology Group and led discovery groups in both Shanghai and Basel, Switzerland. In 2015 he became the Leader of the China Acceleration Strategy for the Roche Infectious Disease group. In 2016 he re-joined Janssen’s Infectious Disease group and continued to work on HBV, as an Early Development Project Team Leader. Dr. Lin obtained his B.S. in Public Health from National Taiwan University, his Master's, and his Ph.D. in Biochemistry from Freie Berlin University in Germany.